Long-Term Results of VisionCare's Implantable Telescope for End-Stage Macular Degeneration Published in the American Journal of Oph... (ears after surgeryversus 20% through 3 m...)

HOME >> MEDICINE >> NEWS

Long-Term Results of VisionCare's Implantable Telescope for End-Stage Macular Degeneration Published in the American Journal of Ophthalmology

Date:11/5/2008

ears after surgery, versus 20% through 3 months and 25% through 12 months

"The long-term results described in this publication reflect years of technical and clinical development in collaboration with the IMT002 Study Group investigators," said Allen W. Hill, CEO of VisionCare. "We are pleased the safety and efficacy results of our pivotal clinical trial have been reported in highly regarded scientific journals like the AJO. VisionCare looks forward to successfully completing the U.S. regulatory review process."

The results are published in the November 2008 issue of the AJO and available on-line at the journal's web site http://www.ajo.com/current. Citation: Hudson HL, Stulting RD, Heier JS, Lane SS, Chang DF, Singerman LJ, Bradford CA, Leonard RE; IMT002 Study Group. Implantable Telescope for End-Stage Age-related Macular Degeneration: Long-term Visual Acuity and Safety Outcomes. Am J Ophthalmol. 2008: 146; 664-673.

About the Telescope Device

The investigational Implantable Miniature Telescope (IMT(TM) by Dr. Isaac Lipshitz) is designed to be a solution for moderate to profound vision loss due to advanced, end-stage forms of AMD that have no current surgical or medical treatment options. Smaller than a pea, the telescope prosthetic device is implanted in one eye in an outpatient surgical procedure. In the implanted eye, the device renders enlarged central vision images over a wide area of the retina to improve central vision, while the non-operated eye provides peripheral vision for mobility and orientation.

The prospective, multicenter IMT002 Phase II/III trial was designed to evaluate the safety and efficacy of VisionCare's investigational medical device in individuals with moderate to profound bilateral central vision impairment associated with End-Stage AMD. A Premarket Approval (PMA) application and subsequent PMA amendments have been submitted to the U.S. Food and Drug
'/>"/>

1

GOOD

Page: 1 2 3 4
Related medicine news :

1. AlBaraka Islamic Bank Builds on a Long-Term Partnership With Misys Selecting Misys Equation and Trade Innovation for its Pakistan Operations
2. GSU study first to confirm long-term benefits of morphine treatment in infants
3. State and National Leaders Call for Long-term Care Financing Reform
4. No Difference in Rate of Survival for Children of Different Races Undergoing Liver Transplantation, but Long-Term Results Not as Good for African-American Adults
5. Early Liver Transplantation Regardless of Donor Type Increases Long-term Survival
6. deCODE Conducting Strategic Review to Sharpen the Focus of its Long-term Business
7. Tennessee Introduces Long-Term Care Partnership Insurance Policies and Producer Training Requirement
8. Getting help for depression and anxiety has significant long-term benefits
9. State Medicaid Programs to Spend $1.6 Trillion on Long-Term Care over the Next Twenty Years
10. Top Insurance Expert Calls on 144,000 Holders of Long-Term Care Polices to Protest an Eleventh Hour Conseco Trust
11. Five Steps for Staying in Financial Control with Long-Term Disability

Post Your Comments:

Long-Term Results of VisionCare's Implantable Telescope for End-Stage Macular Degeneration Published in the American Journal of Oph...(ears after surgeryversus 20% through 3 m...),Health